Dundee Corporation Portfolio Holding, TauRx Pharmaceuticals Ltd., Announces Move Toward Regulatory Submission Following Initial Data From LUCIDITY Trial
yahoo.com
news
2022-05-31 21:52:00

Dundee Corporation

TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the 'Corporation' or 'Dundee') today announces that TauRx Pharmaceuticals Ltd. ('TauRx'), a leader in tau-based research in Alzheimer's, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx's official announcement, please visit:

https://ts-assets.ams3.cdn.digitaloceanspaces.com/mg/tx/pdfs/Lucidity-Data-Announcement.
